Semaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic drug makers has already lined up the launch of their generic semaglutide drugs immediately after the patent expiry, prompting the company to brace up for the upcoming competition in the GLP-1 market.
